New Zealand markets open in 7 hours 57 minutes
  • NZX 50

    11,316.81
    -26.06 (-0.23%)
     
  • NZD/USD

    0.5933
    -0.0014 (-0.24%)
     
  • ALL ORDS

    7,229.80
    -8.50 (-0.12%)
     
  • OIL

    92.34
    +1.95 (+2.16%)
     
  • GOLD

    1,909.40
    -10.40 (-0.54%)
     

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?